Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma exchange (plasmapheresis)

G R Hughes

    Agents and Actions. Supplements
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Plasma exchange (plasmapheresis) may improve chronic rheumatic diseases like lupus and rheumatoid arthritis by enhancing reticulo-endothelial system function. This therapy removes inflammatory mediators, offering potential benefits beyond transient antibody reduction.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Minocycline-induced arthritis.

    Clinical and experimental rheumatology·1998
    Same author

    Does SLE flare during pregnancy?

    Scandinavian journal of rheumatology. Supplement·1998
    Same author

    Therapeutic advances in systemic lupus erythematosus.

    Current opinion in rheumatology·1998
    Same author

    Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein.

    British journal of rheumatology·1998
    Same author

    Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome.

    British journal of rheumatology·1998
    Same author

    Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.

    Arthritis and rheumatism·1998
    Same journal

    Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

    Agents and actions. Supplements·1998
    Same journal

    Immunomodulation of Crohn's disease by interleukin-10.

    Agents and actions. Supplements·1998
    Same journal

    Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

    Agents and actions. Supplements·1998
    Same journal

    Symposium new drugs for inflammatory, allergic and immunologic disease.

    Agents and actions. Supplements·1998
    Same journal

    The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

    Agents and actions. Supplements·1998
    Same journal

    A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

    Agents and actions. Supplements·1998
    See all related articles

    Area of Science:

    • Immunology
    • Rheumatology
    • Therapeutic Apheresis

    Background:

    • Plasma exchange (plasmapheresis) is a therapy involving the exchange of patient plasma with a substitute.
    • Historically used for antibody-mediated diseases like Goodpasture's syndrome and Myasthenia Gravis.
    • Efficacy in chronic rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) is less established, with prior data being insufficient.

    Purpose of the Study:

    • To evaluate the therapeutic potential of plasmapheresis in chronic rheumatic diseases.
    • To investigate the effects of plasmapheresis on disease activity and immune parameters in SLE and RA.
    • To explore the impact of plasmapheresis on reticulo-endothelial system (RES) function in these conditions.

    Main Methods:

    Related Experiment Videos

  • Review of uncontrolled trials and clinical observations regarding plasmapheresis in SLE and RA.
  • Monitoring of antibody titers, immune complex levels, and clinical disease activity.
  • Assessment of reticulo-endothelial system (RES) function using heat-damaged red blood cell clearance rates.

    • Main Results:

    • Plasmapheresis has shown potential in improving vasculitis and arthritis associated with SLE and RA.
    • While antibody titers may show transient improvement, clinical benefits and reduced immune complex levels can persist longer.
    • Impaired RES function, common in SLE and RA, appears to be improved by plasmapheresis, potentially by reducing immune complex load.

    Conclusions:

    • Plasmapheresis may offer therapeutic benefits in chronic rheumatic diseases beyond antibody reduction.
    • Improved RES function following plasmapheresis could contribute to sustained clinical improvements.
    • Further controlled studies are warranted to confirm the efficacy and mechanisms of plasmapheresis in SLE and RA.